A Review of Recent Pharmacological Advances in the Management of Diabetes-Associated Peripheral Neuropathy

“

TL;DR

This narrative review summarizes current pharmacological treatments for diabetic peripheral neuropathy (DPN), including SNRIs, gabapentinoids, and TCAs, and highlights emerging therapies such as GLP-1 agonists and mirogabalin. Up to 25% of DPN patients experience pain, and current monotherapy fails to provide adequate relief for about two-thirds of patients, underscoring the need for new treatments. The review concludes that while GLP-1 agonists show promise in preclinical and small clinical studies, large-scale trials are still needed to confirm their efficacy in DPN.

Full summary

3,882 CHARS

**Background:** Diabetic peripheral neuropathy (DPN) is a common complication of diabetes mellitus, with distal sensorimotor polyneuropathy (DSMP) accounting for 75–90% of cases. Up to 25% of DSMP patients experience pain as their main symptom. The prevalence of DSMP is estimated at 15% in newly diagnosed diabetes, rising to 50% after 10 years. DPN imposes a significant burden: 43% of patients use concomitant medication for anxiety, depression, or sleep deprivation, and diabetic neuropathy contributes to an estimated 27% of total annual diabetes management costs. This review aims to highlight current pharmacological treatments and emerging therapies for DPN.

**Methods:** This is a narrative review that summarizes evidence from systematic reviews, meta-analyses, and clinical trials. The authors draw on the 2022 American Academy of Neurology (AAN) practice guidelines and the 2023 American Diabetes Association (ADA) standards of care. The review covers symptomatic treatments (SNRIs, gabapentinoids, sodium channel blockers, TCAs) and pathogenesis-based treatments (GLP-1 agonists, SGLT-2 inhibitors). A table of 18 key studies is provided, including systematic reviews, meta-analyses, randomized controlled trials, and cross-sectional studies.

**Key Results:** - **SNRIs:** Duloxetine is considered first-line. A Cochrane review found a relative rate of >50% pain improvement of 1.53 (95% CI) for duloxetine vs. placebo. A 2023 systematic review found duloxetine 120 mg/day provides pain relief without increased side effects compared to 60 mg/day. A 2021 meta-analysis found no significant difference between duloxetine and gabapentin for DPN pain. - **Gabapentinoids:** Pregabalin is FDA-approved for painful DPN. Mirogabalin (15–30 mg/day) showed significant pain reduction vs. placebo in a 5-week trial (mean ADPS change −2.66 to −2.79 vs. −1.86 for placebo). A 14-week trial with 834 patients found statistically significant pain reduction only for the 30 mg/day dose. - **Sodium channel blockers:** A 2020 systematic review of 43 RCTs found lidocaine 700 mg medicated plaster equivalent to pregabalin for peripheral neuropathic pain, with a better adverse event profile. - **TCAs:** A 2022 network meta-analysis found amitriptyline improved quality of life and pain, but duloxetine 120 mg was more beneficial. The OPTION-DM trial (130 patients, 50 weeks) found that supplementing amitriptyline with pregabalin resulted in no statistically significant difference in pain outcomes compared to other combinations; monotherapy did not provide significant relief for about two-thirds of participants. - **GLP-1 agonists:** A meta-analysis of 34 RCTs showed GLP-1 agonists lower HbA1c by 0.55% to 1.21%. A 2022 retrospective cohort of 101,440 patients found GLP-1 agonist use associated with significantly reduced risks of major adverse limb events. A cross-sectional study of 473 patients found a statistically significant decrease in fasting GLP-1 levels (approximately 1.5 pmol/L) in male patients with DPN. A 2021 study of 90 patients found exenatide improved nerve excitability measures, with no correlation to HbA1c or blood pressure changes. - **SGLT-2 inhibitors:** No large clinical trials have assessed DPN outcomes. One meta-analysis found no difference between SGLT-2 inhibitors and GLP-1 agonists for limb amputation rates.

**Clinical Implications:** Current first-line therapies (SNRIs, gabapentinoids) provide moderate efficacy, but many patients do not achieve adequate pain relief. Combination therapy may be more effective, but a significant number of patients remain refractory. Emerging therapies such as mirogabalin (approved in Japan) and GLP-1 agonists show promise, but large-scale trials are needed. The review highlights the need for pharmacogenetic studies to personalize treatment and for research into the optimal timing of polypharmacy.